The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial

OBJECTIVE: Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa (FXIIa)-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant functi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arterioscler Thromb Vasc Biol
Main Authors: Lorentz, Christina U., Verbout, Norah G., Wallisch, Michael, Hagen, Matthew W., Shatzel, Joseph J., Olson, Sven R., Puy, Cristina, Hinds, Monica T., McCarty, Owen J.T., Gailani, David, Gruber, András, Tucker, Erik. I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494446/
https://ncbi.nlm.nih.gov/pubmed/30700130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.118.312328
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados